Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
224 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (4)

Medical Condition

  • Show all (1221)
  • Addiction (16)
    • Alcohol (1)
    • Cocaine (2)
    • (-) Marijuana (2)
    • Nicotine (3)
    • Opioids (7)
  • Allergy, Asthma, & Immunology (13)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (18)
  • Bone & Muscle (10)
  • Cancer (102)
    • Brain Cancer (3)
    • Breast Cancer (13)
    • Gastrointestinal (2)
    • Gynecologic Cancer (30)
    • Kidney Cancer (1)
    • Leukemia (9)
    • Liver Cancer (2)
    • Lung Cancer (4)
    • Lymphoma (10)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (2)
    • Prostate Cancer (3)
    • (-) Sarcoma (2)
    • Skin Cancer (2)
    • Solid Tumors (4)
  • Child Development (4)
  • COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (12)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (26)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (187)
  • Heart Disease (130)
  • Infectious Disease (48)
  • Insomnia (3)
  • Kidney Disease (12)
  • Liver Disease (52)
  • Lung Disease (31)
  • Meniere's Disease (1)
  • Neurological Disorders (126)
  • Nutrition (5)
  • Obesity (9)
  • Obstetrics & Gynecology (55)
  • Pain Management (1)
  • Pediatrics (98)
  • Psychiatric Disorders (67)
  • Rehabilitation (9)
  • Stroke (7)
  • Surgery (7)
  • Transplant (45)
  • Urology (3)
  • Vascular Conditions (10)
Displaying 1 - 4 of 4

Study of ATX-101 in Patients with Dedifferentiated Liposarcoma (LPS) and Leiomyosarcoma (LMS)

Condition: Cancer / Sarcoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for cancer…
Read More

Study of Brain Activity and Decision-Making in Marijuana Smokers

Condition: Addiction / Marijuana
Investigator: Suzette Evans, PhD
Status: Closed
RESEARCH VOLUNTEERS: Healthy male and female (age 21-60) MARIJUANA SMOKERS needed to study effects of marijuana on brain activity and decision-making. The study involves 2-3 outpatient visits and a 5-day/5-night stay at the NYS Psychiatric Institute and includes Magnetic Resonance Imaging (MRI) scans. Compensation for time could be between $870-$1230 (…
Read More

Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors - DUPLICATE

Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Read More

Medication treatment of marijuana use and Attention-Deficit/Hyperactivity disorder

Condition: Addiction / Marijuana
Investigator: Frances Levin, MD
Status: Closed
The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science